Our People to Live Stronger & Longer

New COVID vaccines coming, but don’t wait!

On the 20th November 2023, ATAGI announced the Therapeutic Goods Administration of Australia has approved new monovalent Omicron XBB 1.5 vaccines which the Australian Government will include in the COVID 19 vaccination program from 11 December 2023.

However, as advised at the Deadly Doctors forum by Dr Kerry Chant and by ATAGI,  due to the recent increase in COVID-19 cases across Australia since November 2023, all people who have not yet had their recommended 2023 doses are encouraged to receive them as soon as possible and should not wait for the new vaccines to become available.

AH&MRC have developed the COVID Booster information poster for member services to help get the message out to community.

Deadly Doctors Forum 2023

The 2023 AH&MRC Deadly Doctors Forum was held on Bidjigal and Gadigal country at the AH&MRC training campus in Little Bay on 11th and 12th of November. This year we provided an expanded program over two-days to allow greater opportunity for doctors working in Aboriginal Community Controlled Health Services (ACCHS) in NSW to connect with peers and receive cultural and clinical education.

There was representation of General Practitioners working at Awabakal, Armajun, Bullinah, Redfern, Biripi, Bulgar Ngaru, Galambila, Illawarra, Katoomba, Katungal, Orange, Riverina, Tamworth, Walhallow, Waminda and Coonamble ACCHSs.

Our Master of Ceremonies for the forum was Keira Edwards, Lead of Cultural Education at AH&MRC.  Aunty Lola Ryan welcomed delegates to country before they had the privilege of participating in the Ochre ceremony led by Susan Moylan-Coombs from the Gaimaragal Group. Susan gave a presentation looking at health through the lens of Indigenous knowledge and was joined by Kiera for a Q&A session to support the GPs’ ongoing journey of cultural learning to help guide them in providing culturally safe care for Aboriginal people.

On 28th November 2023 legislation comes into effect legalising Voluntary Assisted Dying (VAD) and Ministry of Health representatives from the NSW Statewide VAD Access Service Sophie Tyner and Dr Christof Slawomirski, presented details of how VAD is being implemented in NSW. The presentation prompted many thoughtful questions from participants and responses were provided not only by the presenters, but also by Dr Kerry Chant who was in the audience and joined in the discussion.

Dr Kerry Chant, the NSW Chief Health Officer’s early arrival to provide a session on Immunisation updates was a highlight of day one. It was a privilege to have her spend time at the forum beyond her own immunisation presentation, providing doctors with the opportunity to hear her responses to questions on VAD Implementation and to listen to feedback and discuss issues for doctors working in the sector.

Holistic Assessment of Developmental and Behavioural disorders in Aboriginal Children/Young People was presented by A/Prof Shanti Raman with Dr. Yvonne Teoh. The case presentation by Dr Teoh, interwoven with A/Prof Raman’s expert insight provided GP’s with valuable ways to approach common but challenging family and children’s presentations.

Cardiologists A/Prof Rachael Cordina and A/Prof Raj Puranick who both provide services at AMS Redfern and Royal Prince Alfred Hospital covered a broad range of cardiovascular topics. Pulmonary Hypertension, Heart Failure management, the new CVD risk calculator, cardiovascular impacts of COVID 19 and Rheumatic Heart Disease were all discussed.

Day two shifted gear from cultural and clinical education to focus on peer connectedness, working together and self-care. Dr Kathryn Hutt from Doctors’ Health NSW helped GPs recognise their own values and how these values can align with their work; the doctors spent time listening to, and connecting with peers and were given advice on developing a personal emergency plan.

Dr Marion Tait from Bulgarr Ngaru Medical Aboriginal Corporation presented “The way to better AMS service delivery” which told the story of a regional systems approach to CQI and education which had been successful in engaging GP’s in the Northern region to collaboratively reflect on performance and implement changes to improve patient care.

Finally, the Public Health team facilitated a session to ask the doctors their views on what could improve the health outcomes of Aboriginal people, what barriers they face in providing evidence based healthcare, solutions to these barriers and what they feel is needed to ensure their continued commitment to working in the sector. The advice from the doctors will be collated and fed back to inform member services of potential initiatives which could attract and retain GP’s.

This two-day forum received overwhelming support and positive feedback from the attendees and we are grateful to all who contributed. We hope to make this a yearly event in addition to other potential initiatives focused on supporting the workforce of GP’s committed to working in the ACCHO sector.

2023-2024 Opioid Treatment Accreditation Course (OTAC) Scholarship

The University of Sydney announced the inaugural launch of the 2023-2024 Opioid Treatment Accreditation Course (OTAC) Scholarship, an initiative aimed at supporting future opioid agonist treatment prescribers in NSW.

The OTAC Scholarship assists general practitioners and nurse practitioners in regional and rural areas of NSW to gain accreditation for opioid pharmacotherapy prescribing in the treatment of opioid dependence. It also recognises and encourages professionals to complete their professional development in opioid dependence treatment and contribute to enhancing the accessibility of opioid dependence treatment services, especially for people living in NSW regional areas.

Each quarter, three eligible recipients of the OTAC Scholarship will receive up to $2,000.

Eligibility for the OTAC Scholarship extends to unaccredited general practitioners and nurse practitioners, currently working in general practice or private settings in regional, rural, and metropolitan areas of NSW, including Aboriginal Medical Services or other community-based clinics. The Scholarship does exclude those working substantively in public settings, such as Local Health Districts or Specialty Networks.

First round applications are now open and will close on Monday 11th December, 2023.

LEARN MORE AND APPLY NOW.

This is a pilot initiative that will run between October 2023 – December 2024. It is funded by the NSW Ministry of Health and administered by the University of Sydney, Specialty of Addiction Medicine.

ID Support NSW

ID Support NSW is a nation-leading unit established by NSW Government dedicated to preventing and responding to data breaches and identity misuse. We are a one-stop-shop assisting individuals affected by scams and fraud and committed to minimising risk and strengthening identity resilience. We have a specialist contact centre of expert advisors trained in the identity recovery process who work with victims to shoulder the burden of remediation as well as advocate on their behalf to protect their identities. We work with industry and the community to improve practices and offer regular free awareness sessions to ensure personal information is kept safe.

People affected by identity misuse or interested in how to keep their personal information safe can contact ID Support on 1800 001 040 Monday to Friday, or visit the website https://www.nsw.gov.au/id-support-nsw for more information, to register for an upcoming event, or to submit an enquiry.

ID Support NSW welcome the opportunity to work with AH&MRC members. Our objective is to introduce our free identity theft education and victim support services to your respective communities, with the ultimate goal of increasing identity theft awareness and protections!

Lachie Blunt from ID Support NSW will be reaching out to all AH&MRC members over the coming weeks, to discuss optimal methods for advertising and promoting ID Support NSW within your medical centres.

Virtual Care Communities

We are reaching out to our network of Aboriginal and Torres Strait Islander communities to invite you to share your unique perspective and voice in an upcoming communication project.

NSW Health have engaged Black Logic to develop targeted communication materials for Aboriginal and Torres Strait Islander peoples. We would greatly appreciate your feedback on these materials through a very brief survey they are conducting.

Your input will play a vital role in shaping future initiatives and ensuring that we provide the best possible communication.

Complete the survey here.

Have more thoughts to share or prefer to have a yarn rather than fill out a survey? We are also hosting a series of focus groups to better understand communication preferences for learning more about virtual care.

Send us an email at sbrims@blacklogic.com.au if you or someone you know is interested in participating.

NSW Section 100 Co-Payment Program

We are pleased to advise that the NSW Health s100 Co-payment Program patient factsheet is now available on the NSW Health website

The factsheet was developed in response to feedback from patient groups and other stakeholders that some patients may not be aware of the s100 Co-payment Program.

The factsheet provides information on

  • Patient eligibility criteria
  • Consent requirements including a link to the 3 Year Patient Consent Form
  • How s100 medicines are dispensed
  • Where patients can find more information about the s100 Co-payment Program.

The factsheet has been translated into ten languages and these are available on the NSW Health website.

Global Bicillin LA (benzathine benzylpenicillin) shortage

We want to highlight an emerging shortage of long-acting benzathine benzylpenicillin, under brand name Bicillin LA. This is an important medication for our sector, particularly for syphilis and Rheumatic Heart Disease. It is also commonly used to treat chest and skin infections in many Aboriginal and Torres Strait Islander communities.

Due to an unexpected increase in global consumer demand, there is limited availability in Australia. NACCHO is aware of a some stockouts/shortages that are already occurring. NACCHO is working closely with TGA and the supplier Pfizer to put measures in place to secure supply for the sector.  The shortage is anticipated to last until late Feb 2024.

For now, we are encouraging the following:

  • Please only order what is needed, wholesalers have been directed to supply no more than 1 month stock at a time
  • Consider prioritising the use of existing supplies only for specific or priority indications, e.g. RHD and syphilis
  • Refer to the TGA website for the most up to date information
  • Please contact pharmacy@naccho.org.au if you have any specific questions or concerns

If you need to access the alternative:

According to advice from the TGA, an international product has been approved for use in Australia under Section 19A.

  • Product: Benzylpenicillin benzathine 1.2 million I.U powder and solvent for suspension for injection (Brancaster Pharma, UK)
  • Approved until: 30 March 2024
  • Sponsor: ORSPEC Pharma 02 4339 4239
  • Please note: CONTAINS SOYA LECITHIN. This product should not be used in patients allergic to peanut or soya.

Unfortunately, this product is costing around $45 per vial (not box of 10 as per Bicillin LA). NACCHO has requested rapid PBS listing, but have been advised this is unlikely until February 2024. Preparation and administration advice is available from Orspec.

Further information:

NACCHO has reached out to suppliers of alternate treatments, to ensure availability of increased quantities and help prevent follow on shortages. For example, we have been advised that extra stock of Septrin liquid is now entering the Australian supply chain. We continue to talk with TGA and PBS to encourage rapid PBS listing of S19A overseas alternatives, to ensure ACCHOs and patients can continue to access appropriate antibiotics at acceptable prices.

We have developed clinician and patient information sheets on Antibiotic shortages with the Australian Commission on Safety and Quality in Healthcare that should be available by the end of the month.

SCREEN YOUR WAY

INVITATION to Screen Your Way – increase cervical screening at your service using tailored, community-led solutions developed with the Eliminate Cervical Cancer team

You are invited to consider working with researchers to prevent and eliminate cervical cancer for Aboriginal and Torres Strait Islander communities.

Screen Your Way aims to increase participation in cervical screening among Aboriginal and Torres Strait Islander women and people with a cervix using self-collection cervical screening.

The Eliminate Cervical Cancer team, led by Associate Professor Lisa Whop (Wagadagam), is based at the National Centre for Aboriginal and Torres Strait Islander Wellbeing Research.

 Screen Your Way aims to support services to increase screening in a sustainable, community-led way, through working with your service and community to design and put in place strategies to increase self-collection and cervical screening in line with your community priorities. This research will be conducted by, with, and for the benefit of Aboriginal and Torres Strait lslander people and communities.

Eligible participating services will be provided with up to $15 000 in direct funding alongside training and resources to support them in implementing their chosen strategies over a 12-month trial period. The ANU team will then evaluate the impact, acceptability and cost effectiveness of strategies using clinical screening data and yarning to providers and clients.

To be eligible, services must meet all of the following criteria: 

  • Be an Aboriginal Community Controlled Health Organisation, or a government primary health care service with a majority of clients being Aboriginal and Torres Strait Islander people;
  • Be located in Queensland, New South Wales or the Northern Territory;
  • Have 120 or more Aboriginal and Torres Strait Islander women or people with a cervix, aged 25-74 years who are active patients;
  • Provide cervical screening and have at least one cervical screening certified health professional or provider;
  • Be able to meet the minimum data requirements, that is consent to provide screening data, related to human papillomavirus testing to allow evaluation of impact.

To submit an Expression of Interest for your service, visit Screen Your Way – Expressions of Interest. Eligible services who submit an expression of interest will be randomly selected to participate.

Visit www.eliminatecxca.com to find out more, submit an expression of interest or get in touch. Or email the research team at eliminatecxca@anu.edu.au for more information.